Ann: Appendix 4D and Half Yearly Financial Report, page-51

Quite frankly Ice if a good deal can’t be done I would rather see it Delist and get 2 appraisals of the true worth of the TAVR IP and the value of the already approved Cardiocell and Vascucell products . As I said this would give a CR a better chance to raise capital at around 10 c rather than staying listed and trying to raise at 2 or 3 c . I see Morningstar Quanttive have been valuing AHZ at 17 c for weeks so how do they base this valuation ? Are they thinking IP value on AHZ products ? At 17 c that gives AHZ a MC of close to 100 million which I feel is a reasonable indication of the IP value , The question is what would AHZ SP be now if they had not run out of cash , 50 c maybe ? Regardless I really hope a deal is forthcoming as no matter which way they go around a CR it’s hard to see it being successful due to the companies previous track record